脑肿瘤患者抗血管生成治疗相关毒性的处理。
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.
机构信息
Department of Integrative Nursing Care, UTHSC-SON, USA.
出版信息
Neuro Oncol. 2012 Oct;14(10):1203-14. doi: 10.1093/neuonc/nor223. Epub 2012 Feb 3.
Abstract
Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.
摘要
抗血管生成治疗，包括贝伐珠单抗，在恶性胶质瘤的治疗中越来越频繁地使用。常见的临床意义重大的毒性包括高血压和蛋白尿、伤口愈合不良和血栓栓塞事件的潜在风险。本文复习了与贝伐珠单抗在恶性胶质瘤中的应用相关的文献，报告了该患者人群中的毒性反应以及这些毒性的处理方法。提供了评估和管理的建议。抗血管生成治疗将继续在恶性胶质瘤的治疗中发挥作用。需要进一步研究这些毒性的预防、评估和管理。
相似文献
1
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.脑肿瘤患者抗血管生成治疗相关毒性的处理。
Neuro Oncol. 2012 Oct;14(10):1203-14. doi: 10.1093/neuonc/nor223. Epub 2012 Feb 3.
2
Anti-angiogenic therapy for high-grade glioma.高级别胶质瘤的抗血管生成治疗。
Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4.
3
Novel anti-angiogenic therapies for malignant gliomas.恶性胶质瘤的新型抗血管生成疗法。
Lancet Neurol. 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6.
4
Antiangiogenic therapy for high-grade glioma.高级别胶质瘤的抗血管生成治疗
Cochrane Database Syst Rev. 2014 Sep 22(9):CD008218. doi: 10.1002/14651858.CD008218.pub3.
5
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.恶性胶质瘤的抗血管内皮生长因子（VEGF）治疗：治疗效果与逃逸机制
Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444.
6
Angiogenesis in malignant glioma--a target for antitumor therapy?恶性胶质瘤中的血管生成——抗肿瘤治疗的一个靶点？
Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93. doi: 10.1016/j.critrevonc.2006.01.004. Epub 2006 Jul 24.
7
Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.按照美国国立癌症研究所不良事件通用术语标准3.0版进行的不良事件分级低估了接受贝伐单抗治疗的胶质瘤患者的高血压副作用。
J Neurooncol. 2016 Mar;127(1):191-200. doi: 10.1007/s11060-015-2031-7. Epub 2015 Dec 31.
8
Anti-angiogenic approaches to malignant gliomas.抗血管生成治疗恶性脑胶质瘤。
Curr Cancer Drug Targets. 2012 Mar;12(3):279-88. doi: 10.2174/156800912799277584.
9
Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.肿瘤血管生成：其机制及在恶性胶质瘤中的治疗意义
J Clin Neurosci. 2009 Sep;16(9):1119-30. doi: 10.1016/j.jocn.2009.02.009. Epub 2009 Jun 24.
10
Targeting angiogenesis in head and neck cancer.针对头颈癌中的血管生成
Semin Oncol. 2008 Jun;35(3):274-85. doi: 10.1053/j.seminoncol.2008.03.005.
引用本文的文献
1
Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer.癌症患者冠状动脉疾病的诊断、临床管理及新出现的策略
Am Heart J Plus. 2025 Jun 26;56:100568. doi: 10.1016/j.ahjo.2025.100568. eCollection 2025 Aug.
2
Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.胶质母细胞瘤中抗血管内皮生长因子（VEGF）治疗的出血和缺血风险
Cancer Gene Ther. 2025 May 21. doi: 10.1038/s41417-025-00914-8.
3
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).癌症靶向治疗和免疫治疗心血管毒性的新见解：超越非阻塞性冠状动脉缺血（INOCA）。
Am Heart J Plus. 2024 Mar 1;40:100374. doi: 10.1016/j.ahjo.2024.100374. eCollection 2024 Apr.
4
Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions.新型冠状病毒肺炎与肺癌的关联：短期和长期相互作用
Cancers (Basel). 2024 Jan 11;16(2):304. doi: 10.3390/cancers16020304.
5
Emergency department imaging utilization of cancer patients treated with bevacizumab: single-institution 8-year experience.接受贝伐珠单抗治疗的癌症患者在急诊科的影像学利用：单机构 8 年经验。
Emerg Radiol. 2023 Aug;30(4):407-418. doi: 10.1007/s10140-023-02136-7. Epub 2023 May 2.
6
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.在晚期肝细胞癌患者中，仑伐替尼治疗下的进行性红细胞增多症。
Cancer Chemother Pharmacol. 2023 Apr;91(4):337-344. doi: 10.1007/s00280-023-04519-6. Epub 2023 Mar 24.
7
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway.靶向蛋白质降解以克服癌症治疗中的耐药性：PROTAC与N-端规则途径
Biomedicines. 2022 Aug 27;10(9):2100. doi: 10.3390/biomedicines10092100.
8
Management of VEGFR-Targeted TKI for Thyroid Cancer.甲状腺癌的VEGFR靶向酪氨酸激酶抑制剂治疗
Cancers (Basel). 2021 Nov 4;13(21):5536. doi: 10.3390/cancers13215536.
9
MicroRNA-485-5p inhibits glioblastoma progression by suppressing E2F transcription factor 1 under cisplatin treatment.microRNA-485-5p 通过抑制顺铂处理下的 E2F 转录因子 1 抑制脑胶质瘤的进展。
Bioengineered. 2021 Dec;12(1):8020-8030. doi: 10.1080/21655979.2021.1982269.
10
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.胶质母细胞瘤的化疗方法及贝伐单抗使用管理的最新进展
Pharmaceuticals (Basel). 2020 Dec 16;13(12):470. doi: 10.3390/ph13120470.
本文引用的文献
1
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.肿瘤放射治疗学组（NRG Oncology）RTOG 0625：贝伐单抗联合伊立替康或剂量密集型替莫唑胺治疗复发性胶质母细胞瘤的随机II期试验。
J Neurooncol. 2017 Jan;131(1):193-199. doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.
2
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.贝伐单抗诱发的可逆性后部白质脑病综合征及胶质母细胞瘤患者的成功再治疗
J Clin Oncol. 2011 Oct 1;29(28):e739-42. doi: 10.1200/JCO.2011.36.1865. Epub 2011 Sep 6.
3
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.一项单药贝伐珠单抗治疗复发性间变性神经胶质瘤患者的 II 期临床试验。
Neuro Oncol. 2011 Oct;13(10):1143-50. doi: 10.1093/neuonc/nor091. Epub 2011 Aug 24.
4
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.AVAglio 研究：贝伐珠单抗联合替莫唑胺和放疗治疗新诊断的多形性胶质母细胞瘤的 3 期临床试验。
Adv Ther. 2011 Apr;28(4):334-40. doi: 10.1007/s12325-011-0007-3. Epub 2011 Mar 14.
5
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.贝伐珠单抗化疗的给药时机影响胸壁端口放置后的伤口愈合。
Cancer. 2011 Mar 15;117(6):1296-301. doi: 10.1002/cncr.25573. Epub 2010 Nov 8.
6
Bevacizumab antiangiogenic therapy for glioblastoma.贝伐单抗用于胶质母细胞瘤的抗血管生成治疗。
Neurology. 2011 Feb 1;76(5):414-5. doi: 10.1212/WNL.0b013e31820a0d7e.
7
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.来那度胺或沙利度胺治疗的多发性骨髓瘤患者的静脉血栓栓塞发生率：系统评价和荟萃分析。
J Thromb Haemost. 2011 Apr;9(4):653-63. doi: 10.1111/j.1538-7836.2011.04215.x.
8
Impact of bevacizumab chemotherapy on craniotomy wound healing.贝伐珠单抗化疗对开颅伤口愈合的影响。
J Neurosurg. 2011 Jun;114(6):1609-16. doi: 10.3171/2010.10.JNS101042. Epub 2010 Dec 10.
9
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.贝伐珠单抗联合替莫唑胺在新诊断的多形性胶质母细胞瘤患者放疗期间和放疗后的 II 期研究。
J Clin Oncol. 2011 Jan 10;29(2):142-8. doi: 10.1200/JCO.2010.30.2729. Epub 2010 Dec 6.
10
Taming glioblastoma by targeting angiogenesis: 3 years later.靶向血管生成治疗胶质母细胞瘤：三年之后
J Clin Oncol. 2011 Jan 10;29(2):124-6. doi: 10.1200/JCO.2010.32.5282. Epub 2010 Dec 6.
Zotero 插件